Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis, Chronic Bronchitis
Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)
This was a randomized multi-center clinical trial to compare the microbiological efficacy, clinical efficacy, and safety of using standard versus biofilm susceptibility testing of P.
- Trial name
- NCT00153634
- Testing
- IV amikacin, PO azithromycin, IV ceftazidime
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Seattle Children's Hospital
Cystic Fibrosis (CF)
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to…
- Trial name
- NCT00677365
- Testing
- MP-376
- Where
- 50 sites in United States, Germany and 1 more
- Volunteers
- 151 people
- Sponsor
- Amgen
Cystic Fibrosis, Pseudomonas Aeruginosa
Volatile Organic Compounds in Cystic Fibrosis
This experiment is designed to test the effectiveness of a new electronic nose device, which allows a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of bacterial…
- Trial name
- VOCCF (NCT01379040)
- Testing
- Cystic Fibrosis patients
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Landon Pediatric Foundation
Cystic Fibrosis
Effect of Glycine in Cystic Fibrosis
The aim of this study is to evaluate if glycine, orally administered in a daily dose of 0.5 g/kg during 8 weeks, can ameliorate the airway inflammation in children with cystic fibrosis, as compared with placebo.
- Trial name
- NCT01417481
- Testing
- Glycine
- Where
- 3 sites in Mexico
- Volunteers
- 13 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
PR-018: An Open-Label, Safety Extension of Study PR-011
A study to evaluate long term safety and effect on ability to thrive of EUR-1008 (APT-1008) 3,000 lipase units (Zenpep® [pancrelipase] delayed release capsules) in infants with exocrine pancreatic insufficiency (EPI) due to…
- Trial name
- NCT01131507
- Testing
- EUR-1008 (APT-1008)
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Forest Laboratories
Cystic Fibrosis
Dynamic Chest X-ray With Simultaneous Spirometry
Dynamic chest X-ray (DCR) is a novel radiographic technique that enables us to visualise the movement of the chest and lungs in real-time by recording a series of x-ray images over 10-20 second interval.
- Trial name
- DynaSSaur (NCT06122051)
- Testing
- Dynamic chest x-ray, Spirometry
- Where
- United Kingdom
- Volunteers
- 104 people
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Osteoporosis, Muscular Dystrophy
Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
By supplying an adequate amount of calcium and vitamin D with the addition of weekly bisphosphonate, the investigators will be able to increase bone mass and decrease the incidence of fragility fractures in these children with…
- Conditions
- Osteoporosis, Muscular Dystrophy, Cystic Fibrosis
- Trial name
- NCT01882400
- Testing
- Bisphosphonate treatment
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Gilles Boire
Cystic Fibrosis (CF), Cystic Fibrosis Pulmonary Exacerbation
Understanding Inflammation, InFection and Interventions in Severe Exacerbations of Cystic Fibrosis
The UNIFIED-CF study is an observational study designed to investigate the impacts of treatment given for severe pulmonary exacerbations in people living with cystic fibrosis (pwCF).
- Trial name
- UNIFIED-CF (NCT07484607)
- Where
- 6 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Alexander Horsley
Cystic Fibrosis
28 Day Repeat Dose in Cystic Fibrosis Patients
The purpose of this study is to determine whether the safety, tolerability and pharmacodynamics of SB656933 in patients that have cystic fibrosis
- Trial name
- NCT00903201
- Testing
- SB656933
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations
Pulmonary exacerbations (PEx) are key events that lead to a decline in health status among CF patients, with many never recovering to baseline health.
- Trial name
- NCT04341532
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor
The academic investigator - initiated trial will evaluate in a postapproval setting whether, and if yes, to what extent and variability, the treatment with lumacaftor in combination with ivacaftor reverses the p.Phe508del CFTR …
- Trial name
- OrkambiFacts (NCT02807415)
- Testing
- Lumacaftor plus Ivacaftor
- Where
- 3 sites in Germany
- Volunteers
- 104 people
- Sponsor
- Hannover Medical School
Cystic Fibrosis
Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)
The purpose of this research study is to test a new combination of medicines, Phenylbutyrate and Genistein, to determine if they could be used to treat cystic fibrosis (CF).
- Trial name
- NCT00590538
- Testing
- Sodium 4-Phenylbutyrate, Genistein (Unconjugated Isoflavones 100)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Children's Hospital of Philadelphia
Cystic Fibrosis
IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
The purpose of this study is to find the safest and most effective way to administer IV antibiotics to treat acute pulmonary exacerbations (APEs) in patients with cystic fibrosis (CF) that are caused by pathogens, like…
- Trial name
- NCT02918409
- Testing
- Colistin, Tobramycin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.
Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-032 in healthy adult subjects (Phase 1) and of two doses in Adults with Cystic Fibrosis (Phase 1b).
- Trial name
- NCT05712538
- Testing
- ARCT-032
- Where
- New Zealand
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Cystic Fibrosis
Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations
The purpose of this study is to explore the combination of Ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation
- Trial name
- NCT03256799
- Testing
- Ivacaftor/Ataluren
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer, Breast Neoplasm
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
The accuracy of breast examinations and ultrasonography performed clinically to detect breast mass varies greatly depending on the physician\'s skill level, and the accuracy of breast examinations by non-experts is…
- Conditions
- Breast Cancer, Breast Neoplasm, Artificial Intelligence, Ultrasonography
- Trial name
- NCT06255808
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Cystic Fibrosis
A Multi-Center Study of the CF Quantum® Sweat Test System
This is an observational comparative study to compare the standard-of-care methods for sweat testing used to support diagnosing cystic fibrosis (CF) against a new method of sweat testing called the CF Quantum Sweat Test System.
- Trial name
- NCT02404714
- Testing
- Iontophoresis sweat test
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- Polychrome Medical, Inc.
Cystic Fibrosis
An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
28-Day double-blinded efficacy and safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.
- Trial name
- (HOPE-1) (NCT03229252)
- Testing
- SPX-101
- Where
- 25 sites in Canada, France and 3 more
- Volunteers
- 91 people
- Sponsor
- Spyryx Biosciences, Inc.
Chronic Respiratory Diseases, Cystic Fibrosis
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Assessment of cardiovascular disorders using echocardiography and arterial stiffness; comparative noninvasive assessment of volatile organic compound (eVOC) exhale breath patterns in patients with different chronic respiratory…
- Conditions
- Chronic Respiratory Diseases, Cystic Fibrosis, Lymphangioleiomyomatosis, Hypersensitivity Pneumonitis
- Trial name
- NCT05727852
- Testing
- Breath test using the Compact PTR-TOF-MS, Portable cardiac monitor "CardioQvark", Assessment of arterial stiffness using the VaSera VS-1500N
- Where
- Russia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Cystic Fibrosis
Airway Microbiome of Cystic Fibrosis Patients
With this study, the investigators first want to investigate the respiratory tract microbiome of cystic fibrosis patients. To achieve this, the investigators will collect longitudinal samples of saliva, throat and sputum and…
- Trial name
- NCT06057558
- Testing
- Probiotic throat spray
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- University Hospital, Antwerp
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.